



Year: 2011

Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition

Rohrmann, S ; Linseisen, J ; Becker, S ; Allen, N ; Schlehofer, B ; Overvad, K ; Olsen, A ; Tjønneland, A ; Melin, B S ; Lund, E ; Vineis, P ; Grioni, S ; Tumino, R ; Palli, D ; Mattiello, A ; Bonet, C ; Chirlaque, M D ; Sánchez, M J ; Rodríguez, L ; Dorronsoro, M ; Ardanaz, E ; Lagiou, P ; Trichopoulou, A ; Trichopoulos, D ; Dossus, L ; Grote, V A ; Boeing, H ; Aleksandrova, K ; Bueno-de-Mesquita, H B ; van Duijnhoven, F J B ; Peeters, P H M ; Khaw, K T ; Wareham, N J ; Key, T J ; Rinaldi, S ; Romieux, I ; Gallo, V ; Michaud, D S ; Riboli, E ; Kaaks, R

Abstract: Background: Insulin-like growth factor-1 (IGF-I) is important in normal brain development but in the adult brain, IGF-I overexpression may be a risk factor for tumor development. Methods: We examined the association between circulating concentrations of IGF-I and IGFBP-3 in relation to risk of gliomas (74 low-grade, 206 high-grade gliomas), meningiomas (n = 174) and acoustic neuromas (n = 49) by using a case-control design nested in the European Prospective Investigation into Cancer and Nutrition. IGF-I and IGFBP-3 were measured by ELISAs. Conditional logistic regression was used to compute ORs and corresponding 95% CIs. Results: The risk of low-grade gliomas was elevated with increased IGF-I (OR = 3.60, 95% CI: 1.11–11.7; top vs. bottom quartile) and decreased with elevated IGFBP-3 concentrations (OR = 0.28, 95% CI: 0.09–0.84) after mutual adjustment of these two factors; these results became nonsignificant after exclusion of the first year of follow-up. No association was observed for high-grade gliomas or meningiomas. Both high IGF-I and IGFBP-3 concentrations were associated with risk of acoustic neuromas (IGF-I: OR = 6.63, 95% CI: 2.27–19.4, top vs. bottom tertile; IGFBP-3: OR = 7.07, 95% CI: 2.32–21.6), even after excluding the first year of follow-up. Conclusion: High concentrations of IGF-I might be positively associated with risk of low-grade gliomas and acoustic neuromas, although we cannot exclude reverse causation, in particular for low-grade gliomas.

DOI: <https://doi.org/10.1158/1055-9965.EPI-11-0179>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-54313>

Journal Article

Accepted Version

Originally published at:

Rohrmann, S; Linseisen, J; Becker, S; Allen, N; Schlehofer, B; Overvad, K; Olsen, A; Tjønneland, A; Melin, B S; Lund, E; Vineis, P; Grioni, S; Tumino, R; Palli, D; Mattiello, A; Bonet, C; Chirlaque, M D; Sánchez, M J; Rodríguez, L; Dorronsoro, M; Ardanaz, E; Lagiou, P; Trichopoulou, A; Trichopoulos, D; Dossus, L; Grote, V A; Boeing, H; Aleksandrova, K; Bueno-de-Mesquita, H B; van Duijnhoven, F J B; Peeters, P H M; Khaw, K T; Wareham, N J; Key, T J; Rinaldi, S; Romieux, I; Gallo, V; Michaud, D S; Riboli, E; Kaaks, R (2011). Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European

Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiology Biomarkers Prevention*,
20(10):2174-2182.
DOI: <https://doi.org/10.1158/1055-9965.EPI-11-0179>

Concentrations of IGF-I and IGFBP3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Sabine Rohrmann^{1,2}, Jakob Linseisen^{1,3}, Susen Becker¹, Naomi Allen⁴, Brigitte Schlehofer⁵, Kim Overvad⁶, Anja Olsen⁷, Anne Tjønneland⁷, Beatrice S Melin⁸, Eiliv Lund⁹, Paolo Vineis^{10,11}, Sara Grioni¹², Rosario Tumino¹³, Domenico Palli¹⁴, Amalia Mattiello¹⁵, Catalina Bonet¹⁶, Maria-Dolores Chirlaque^{17,18}, María-José Sánchez^{19,18}, Laudina Rodríguez²⁰, Miren Dorronsoro^{21,18}, Eva Ardanaz^{22,18}, Pagona Lagiou^{23,24}, Antonia Trichopoulou^{23,25}, Dimitrios Trichopoulos^{24,26}, Laure Dossus¹, Verena A. Grote¹, Heiner Boeing²⁷, Krasimira Aleksandrova²⁷, H Bas Bueno-de-Mesquita^{28,29}, Fränzel JB van Duijnhoven²⁸, Petra HM Peeters³⁰, Kay-Tee Khaw³¹, Nicholas J Wareham³², Timothy J Key³³, Sabina Rinaldi³⁴, Isabelle Romieux³⁴, Valentina Gallo⁸, Dominique S Michaud³⁵, Elio Riboli³⁵, Rudolf Kaaks¹

¹Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany

²University of Zurich, Institute of Social and Preventive Medicine, Zürich, Switzerland

³Institute of Epidemiology, Helmholtz Zentrum München, Munich, Germany

⁴Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

⁵Group of Environmental Epidemiology, German Cancer Research Center, Heidelberg, Germany

⁶Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark

⁷Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark

⁸Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden

⁹Institute of Community Medicine, University of Tromsø, Tromsø, Norway

¹⁰MRC/HPA Centre for Environment and Health, School of Public Health, Imperial College London

¹¹HuGeF Foundation, Torino, Italy

¹²Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

¹³Cancer Registry and Histopathology Unit, "Civile M.P.Arezzo" Hospital, Ragusa, Italy

¹⁴Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy

¹⁵Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy

¹⁶Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO), Barcelona, Spain.

¹⁷Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain

¹⁸ Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública-CIBERESP)

¹⁹Escuela Andaluza de Salud Pública, Granada, Spain

²⁰Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain

²¹Public Health Department of Gipuzkoa, Spain Department of Public Health of Gipuzkoa, San Sebastian, Spain

²²Navarre Public Health Institute, Pamplona, Spain

²³WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Greece

²⁴Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

²⁵Hellenic Health Foundation, Athens, Greece

²⁶Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece

²⁷Department of Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany

²⁸National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands

²⁹Department of Gastroenterology and Hepatology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands.

³⁰Julius Center, University Medical Center Utrecht, Utrecht, The Netherlands;

³¹Department of Public Health and Primary Care, University of Cambridge, UK

³²Medical Research Council (MRC) Epidemiology Unit, Cambridge, UK

³³Cancer Research UK, Epidemiology Unit, University of Oxford, UK

³⁴International Agency for Research on Cancer (IARC), Lyon, France

³⁵Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College, London, UK

Running title: IGF-I, IGFBP-3 and brain tumor risk

Key words: IGF-I, IGFBP-3, brain tumor, cohort study

Word count: Abstract: 244

Text: 3566

Number of tables: 3

Corresponding Author

Sabine Rohrmann

University of Zurich

Institute of Social and Preventive Medicine

Hirschengraben 84

8001 Zürich

Switzerland

phone +41 44 634 5256

e-mail sabine.rohrmann@ifspm.uzh.ch

1 **Abstract**

2 Background: Insulin-like growth factor-1 (IGF-I) is important in normal brain
3 development, but in the adult brain IGF-I overexpression is a signal for neoplastic
4 processes.

5 Methods: We examined the association between circulating concentrations of IGF-I
6 and IGFBP3 in relation to risk of gliomas (74 low-grade, 206 high-grade gliomas),
7 meningiomas (n=174) and acoustic neuromas (n=49) using a case-control design
8 nested in the European Prospective Investigation into Cancer and Nutrition. IGF-I
9 and IGFBP3 were measured by enzyme-linked immunosorbent assays. Conditional
10 logistic regression was used to compute odds ratios (OR) and corresponding 95%
11 confidence intervals (CI).

12 Results: The risk of low-grade gliomas was elevated with increased IGF-I (OR=3.60,
13 95% CI 1.11-11.7; top vs. bottom quartile) and decreased with elevated IGFBP-3
14 concentrations (OR=0.28, 95% CI 0.09-0.84) after mutual adjustment of these two
15 factors; these results became non-significant after exclusion of the first year of follow-
16 up. No association was observed for high-grade gliomas or meningiomas. Both high
17 IGF-I and IGFBP-3 concentrations were associated with risk of acoustic neuromas
18 (IGF-I: OR=6.63, 95% CI 2.27-19.4, top vs. bottom tertile; IGFBP-3: OR=7.07, 95%
19 CI 2.32-21.6), even after excluding the first year of follow-up.

20 Conclusion: High concentrations of IGF-I might be positively associated with risk of
21 low-grade gliomas and acoustic neuromas, although we cannot exclude reverse
22 causation for low-grade gliomas.

23 Impact: Factors of the IGF axis might be involved in the etiology of some types of
24 brain tumors.

1 **Introduction**

2 Tumors of the brain vary widely by degree of malignancy; high-grade gliomas
3 tend to produce more severe and rapidly progressive symptoms whereas low-grade
4 gliomas, meningiomas and acoustic neuromas typically produce less severe,
5 intermittent or slowly progressive symptoms. Besides increasing age, high-dose
6 radiation, and some hereditary syndromes, no risk factors for brain tumors have been
7 established and the etiology of brain tumors remains largely unknown (1).

8 Insulin-like growth factors (IGFs) are multifunctional peptides that regulate cell
9 proliferation, differentiation, and apoptosis (2). IGF-I is important in normal brain
10 development to promote the growth process, and deletion of the IGF-I gene is
11 associated with reduced brain growth and mental retardation (3). In the adult brain,
12 by contrast, IGF-I over-expression is a signal for neoplastic processes (4), and IGF-I
13 and -II genes are regularly found to be over-expressed in gliomas and meningiomas
14 (5). In vitro, IGF-I receptor and IGF binding proteins promote mitogenesis and
15 differentiation in glial cells, oligodendrocytes, and neural cells (5). While most of IGF-I
16 and its binding proteins in the circulation is produced by the liver (6), these peptides
17 are also synthesized locally in most other organs, including the brain and other
18 neural tissues (7). The actions of IGF-I on neural tissues are influenced by the
19 endocrine effects of circulating IGF-I, which can enter the central nervous system
20 (CNS) (5), and paracrine or autocrine effects of IGF-I produced within the tissue
21 itself.

22 The hepatic production of IGF-I and of its major plasmatic binding protein
23 IGFBP-3 is stimulated by growth hormone (GH) (8). Adult height relates to
24 longitudinal growth rates during childhood and adolescence, which are strongly
25 influenced by levels of IGF-I, although the association of final body stature with

1 circulating IGF-I levels during adulthood is less strong (10). Recently, body height
2 was found to be positively associated with glioma risk in a US cohort study (9). In
3 EPIC, body height was associated with IGF-I levels in men, but not in women (11).
4 Acromegaly, a condition resulting from excessive growth hormone secretion, has
5 also been found to be associated with an increased risk of CNS tumors (12),
6 although this may partly be due to pituitary irradiation for treating the adenomas
7 responsible for the condition.

8 To date, only one small nested case-control study with 22 glioma cases and
9 400 controls examined the associations between serum concentrations of IGF-I and
10 IGF binding protein (BP)-3, the most important binding protein of circulating IGF-I (8),
11 and glioma risk (13). The authors reported inverse associations of gliomas with both
12 IGF-I and IGFBP-3 concentrations, although only the association between circulating
13 IGF-I and gliomas was statistically significant. This observation is not consistent with
14 findings from many studies that observed direct associations between circulating
15 IGF-I and the risks of several other types of cancer (14), and contrasts with
16 observations from experimental and histo-pathological studies indicating that IGF-I
17 may promote tumor development in the central nervous system (4, 15).

18 The aim of this study was to examine the association of IGF-I and IGFBP-3
19 concentrations with the risk of gliomas, meningiomas, and acoustic neuromas in a
20 case-control study nested within the European Prospective Investigation into Cancer
21 and Nutrition (EPIC).

23 **Material and Methods**

24 *Study description.*

1 EPIC is a prospective cohort study designed to examine the association of diet
2 and lifestyle with the risk of cancer and other chronic diseases. The cohort
3 comprising a total of more than 500.000 male and female participants was recruited
4 in 23 centers in 10 European countries. Participants were recruited between 1992
5 and 2000; most centers recruited subjects from the general population, but in Utrecht
6 and Florence only women from breast cancer screening programs were recruited.
7 Additionally, the Spanish and Italian centers include blood donors and the French
8 cohort consists of members of a health insurance for state school employees. A high
9 proportion of participants of the Oxford cohort are vegetarians or health-conscious
10 volunteers. The cohorts of France, Utrecht, Florence, and Norway include women
11 only.

12 Information on lifestyle and diet was collected during baseline examination.
13 Diet was assessed using country-specific validated dietary assessment instruments
14 (16, 17). Information on lifestyle factors such as smoking, alcohol consumption, or
15 physical activity, but also on education, occupation, or medical and reproductive
16 history has been collected using questionnaires and personal interviews.
17 Anthropometric measurements have been conducted during baseline examination
18 (18).

19 Following a standardized protocol, a blood sample of 30 mL was collected in
20 all participating EPIC countries. In most centers, except Oxford, blood samples were
21 stored protected from light at 5-10 °C until further processing and aliquoting. In the
22 Oxford center, blood samples were collected throughout the United Kingdom and
23 transported to the laboratory in Norfolk by mail at ambient temperature. In all centers
24 except Denmark and Sweden, 0.5 ml aliquots of serum, plasma, red blood cells, and
25 buffy coat were filled into plastic straws and stored in liquid nitrogen at -196 °C. In the

Danish centers, 1 ml aliquots were filled into tubes and stored in the vapor phase of liquid nitrogen containers (-150°C). In Sweden, the samples were stored at -80 °C.

Case assessment and matching.

The follow-up in EPIC is based on population cancer registries in Denmark, Italy, Netherlands, Spain, Sweden, United Kingdom and Norway. In Germany and Greece a combination of methods including health insurance records, cancer and pathology registries, and active follow-up through study subjects and their next-of-kin was used. Mortality data are also collected from either the cancer registry or mortality registries at the regional or national level. For each EPIC center, closure dates of the study period were defined as the latest dates of complete follow-up for both cancer incidence and vital status (dates varied between centers, from December 2002 to December 2006).

By December 2006, 799 histologically confirmed primary brain tumor cases have been recorded in the EPIC database. Of these, we excluded 102 cases because they did not provide a blood sample at recruitment and a further 103 cases because the diagnosis was unspecified beyond that of primary brain tumor (ICD-O M8000). Cases from the center from Malmö were not available for our analyses (n=68); France was excluded from the analysis as self-reported brain tumors had not been histologically confirmed when the study was initiated. Nineteen cases were excluded because of technical problems or insufficient serum volume. The final analytical sample included 505 primary brain tumors, namely 282 gliomas [International classification of diseases for oncology (ICD-O) codes M9380 – M9473], 176 meningiomas (ICD-O M9530-M9539), and 49 acoustic neuromas (ICD-O M9540). In addition, glioma cases were divided into high grade-glioma (ICD-O codes: M9440/3, M9441/3, M9442/3, M9401/3, M9380/3, M9451/3) and low grade-glioma

(ICD-O codes: M9382/3, M9383/1, M9384/1, M9390/0, M9394/1, M9400/3, M9411/3, M9420/3, M9421/3, M9450/3, M9505/1, M9391/3).

Two controls per case were selected, matched for gender, study (recruitment) centre, age at recruitment, date at blood donation, and fasting status at blood donation (time since last consumption of foods or drinks; last meal < 6, 3-6, or <3 hours before blood draw).

Hormone assays.

Serum IGF-I and IGFBP-3 concentrations were measured in the Immunoassay Laboratory at the German Cancer Research Center, Heidelberg, Germany. Both peptides were analyzed by enzyme-linked immunosorbent assays (ELISAs) purchased from Beckman Coulter. Prior to total IGF-I analysis, IGF-I was separated from IGF-I binding proteins by an acid-ethanol extraction step. Cases and matched controls were measured in singleton within the same batch. Each analytical batch further included three different serum quality control samples. Laboratory staff was blinded to the case/control status of the study samples. Mean intra- and inter-batch coefficients of variation were 2.9% and 14.4% respectively for IGF-I and 1.7% and 15.5% respectively for IGFBP-3.

Statistical analysis.

To examine the association of IGF-I, IGFBP-3, and molar IGF-I/IGFBP-3 ratio with BMI, Spearman's partial coefficients of correlation adjusted for age, sex and EPIC recruitment center were computed.

Conditional logistic regression was used to examine the association of IGF-I and IGFBP-3 concentrations with brain tumor risk. We also computed the molar ratio of IGF-I to IGFBP-3 (IGF-I/IGFBP-3 ratio) as a marker of the estimated IGF-I level

1 biologically available to bind to its receptor. Concentrations of IGF-I and IGFBP-3 as
2 well as IGF-I/IGFBP-3 ratio were categorized into quartiles based on the distribution
3 among all controls. Due to the small number of acoustic neuromas, we used tertiles
4 instead of quartiles to examine the respective associations.

5 Crude models took into account matching criteria; multivariate models
6 additionally adjusted for body mass index (BMI) (in sex-specific quartiles) or waist-hip
7 ratio (WHR) (alternatively; in sex-specific quartiles), education (primary school or
8 less; secondary school; vocational training; university; missing), smoking history
9 (never, former, current, missing), and physical activity (active, moderately active,
10 moderately inactive, inactive). Adjustments for these factors did not appreciably
11 change any of the results and therefore were excluded from the final models. Thus,
12 only the matching criteria (age, gender, center, follow-up time, time of the day of
13 blood draw, and fasting status) remained as implicit adjustments controlled for
14 through the conditional regression models. Further analyses were conducted with
15 mutual adjustments between IGF-I and IGFBP-3 concentrations.

16 In sub-analyses, in which we stratified by sex, age at diagnosis (≤ 60 years
17 at diagnosis), BMI (\leq median BMI), and length of follow-up (\leq median follow-up
18 time in cases = 4.4yrs), odds ratios (OR) were estimated for continuous
19 measurements IGF-1, IGFBP-3, and IGF-I/IGFBP-3 ratio transformed on the log₂
20 scale. In this scale, a unit increase corresponds to a doubling of concentration.
21 Statistical tests for heterogeneity by sex, age at diagnosis, BMI, and length of follow-
22 up were based on chi-square statistics, calculated as the deviations of logistic beta-
23 coefficients observed in each of the subgroups, relative to the overall beta-coefficient.
24 Finally, we performed sub-analyses excluding cases diagnosed within the first year of

1 follow-up to examine potential 'reverse causation' bias. All analyses were conducted
2 with SAS version 9.1.

4 **Results**

5 The median time between date of study recruitment and diagnosis of tumor
6 among cases was 4.4 years (glioma 4.5, meningioma 4.2, acoustic neuromas 4.1).
7 Baseline characteristics of cases and controls are shown in Table 1. Cases and
8 controls did not differ by selected baseline characteristics except that meningioma
9 cases had a slightly higher BMI than controls. In controls, circulating levels of IGF-I
10 were not statistically significantly correlated with BMI (Spearman $r = 0.01$; p-value
11 0.77), but there were significant correlations of IGFBP-3 (Spearman $r = 0.15$; p-value
12 <0.01) and molar IGF-I/IGFBP-3 ratio (Spearman $r = -0.09$; p-value <0.01) with BMI.

13 **Gliomas.** High IGF-I or high IGFBP-3 concentrations were not statistically
14 significantly associated with glioma risk (Table 2). The strength of the relationship of
15 IGF-I and IGFBP-3 with gliomas was slightly attenuated after mutually adjusting for
16 the two factors. Likewise, there was no significant association between molar IGF-
17 I/IGFBP3 ratio and glioma risk. Excluding the first year of follow-up to examine a
18 potential reverse causation bias did not change the associations between the
19 measured biomarkers and glioma risk (IGF-I: 1.11, 95% CI 0.68-1.81, top vs. bottom
20 quartile; IGFBP-3: 0.92, 0.58, 1.46; IGF-I/IGFBP-3: 1.13, 0.67, 1.91).

21 We conducted sub-group analyses to examine whether the associations between
22 factors of the IGF-system differed by sex, BMI, age at tumor diagnosis, or length of
23 follow-up. Besides a statistically significant effect modification of the association
24 between IGFBP-3 concentration and glioma risk by BMI, we did not observe major

differences between these sub-groups (data not shown). Per doubling in IGFBP-3 concentration, glioma risk decreased by more than 50% (OR=0.48, 95% CI 0.23-0.99) in subjects with normal BMI, but no statistically significant association was seen in obese subjects (OR=1.26, 95% CI 0.67-2.36; p-heterogeneity=0.048).

High- vs. low-grade gliomas. After stratifying by tumor grade, neither IGF-I nor IGFBP-3 concentrations were associated with the risk of high-grade gliomas (Table 3). However, although IGF-I and IGFBP-3 were not associated with low-grade gliomas in the basic model, a high IGF-I concentration was related to an increased risk of low-grade gliomas after additionally adjusting for IGFBP-3 concentration (OR=3.60, 95% CI 1.11-11.7; top vs. bottom quartile). In contrast, IGFBP-3 concentration was inversely associated with low-grade gliomas after adjusting for IGF-I (OR=0.28, 95% CI 0.09-0.84). A high IGF-I/IGFBP-3 ratio was associated with a non-statistically significant increase in low-grade glioma risk in the categorical model; a two-fold increase in the ratio yielded an OR=2.80 (95% CI 0.98-7.98). Excluding the first year of follow-up resulted in an attenuated association of IGF-I (OR=1.23, 95% CI 0.45-3.36 [2.05, 0.59-7.13 adjusted for IGFBP-3]; top versus bottom quartile), IGFBP-3 (OR=0.54, 95% CI 0.21-1.38 [0.34, 0.11-1.07 adjusted for IGF-I]; top versus bottom quartile), and IGF-I/IGFBP-3 (OR=2.01, 95% CI 0.68-5.92; top versus bottom quartile) with low-grade gliomas.

Meningiomas. As for gliomas, circulating levels of IGF-I and IGFBP-3 as well as the IGF-I/IGFBP-3 ratio were not associated with meningioma risk (Table 2). Excluding the first year of follow-up did not materially alter the observed associations for IGF-I or IGFBP-3, respectively (IGF-I: OR 1.13, 95% CI 0.61, 2.09, top vs. bottom quartile; IGFBP-3: 1.71, 0.90, 3.27; IGF-I/IGFBP-3: 0.87, 0.47, 1.64).

1 In subgroup analyses, we observed statistically significant heterogeneity in the
2 association between IGF-I/IGFBP-3 ratio and meningioma risk by sex and age (data
3 not shown). The IGF-I/IGFBP-3 ratio was significantly inversely associated with
4 meningioma risk in men (OR=0.21, 95% CI 0.06-0.75 per doubling in ratio), but not in
5 women (OR=1.23, 95% CI 0.65-2.33, p-heterogeneity=0.02). Furthermore, the IGF-
6 I/IGFBP-3 ratio was significantly inversely associated with meningioma risk in young
7 (< 60 years of age at diagnosis; OR=0.43, 95% CI 0.19-0.98 per doubling in ratio),
8 but not in older cases (OR=1.72, 95% CI 0.74-4.01, p-heterogeneity=0.02).

9 **Acoustic neuromas.** We observed positive associations of circulating IGF-1 and
10 IGFBP-3 concentrations and acoustic neuromas (Table 2). These associations were
11 attenuated after mutual adjustments between the two peptides, although the ORs in
12 the highest tertiles remained significantly increased compared with the bottom
13 tertiles. As expected, the IGF-I/IGFBP-3 ratio showed no association with risk of
14 acoustic neuroma. The results did not change strongly after we excluded cases that
15 occurred during the first year of follow-up (IGF-1: OR 6.93, 95% CI 2.24-21.5, top vs.
16 bottom tertile; IGFBP-3: 6.09, 1.94-19.1; IGF-I/IGFBP-3: 2.66, 0.82-8.67). No
17 statistically significant heterogeneity by age at diagnosis, length of follow-up, BMI,
18 and sex were observed (data not shown).

20 Discussion

21 This is the first large nested case-control study to examine the association of
22 circulating concentrations of IGF-I and its most important binding protein IGFBP-3
23 with the risk of different types of brain tumor, namely high- and low-grade gliomas,
24 meningiomas and acoustic neuromas. We did not observe a general association

1 between IGF-I or IGFBP-3 concentrations or the molar ratio of IGF-I to IGFBP3 with
2 risk of gliomas and meningiomas. However, subjects with high circulating levels of IGF-
3 I had an increased risk and those with a high level of IGFBP-3 had a decreased risk
4 of low-grade gliomas after mutual adjustments between IGF-I and IGFBP-3.
5 Additionally, we observed that both concentrations of IGF-I and IGFBP3 were
6 positively associated with the risk of acoustic neuromas.

7 High circulating concentrations of IGF-I and IGF binding proteins have been
8 found to be associated with increased risks of several types of cancers, including
9 cancers of the colon (19), prostate (20), or breast cancer (21). There is increasing
10 evidence that IGFs play an important role in the growth and differentiation of the
11 central nervous system and specific receptors for IGF-I and IGF-II have been
12 identified in normal human brain (15). IGF pathways show similar expression and
13 functional features during central nervous system development and tumorigenesis (8,
14 22, 23). IGFs have been reported to be over-expressed to varying degrees in central
15 nervous system tumors, such as glioma (4, 15), and in vitro studies have shown that
16 IGF-I promotes mitogenesis and differentiation in glial cells (24, 25). IGF binding
17 proteins prolong the half-life of IGF-I by competing with IGF-I receptor for binding
18 IGF-I. In addition, IGFBP-3 may have intrinsic growth inhibiting and pro-apoptotic
19 effects independent of sequestering IGF-I (26, 27), although in some experimental
20 studies it has also been observed to exert growth-promoting effects (28). IGFBP
21 expression can increase neoplastic processes, for example in gliomas (29). IGF-I is
22 produced by the liver, but also in the brain and the spinal cord (22). It has been
23 shown that circulating IGF-I enters the brain and the spinal cord via a saturable
24 transport system at the brain-blood barrier (7). The half-life of IGF-I and the rate of
25 entry of IGF-I into the central nervous system are likely to be related to the
26 concentration of IGFBPs in the circulation (7). Vice versa, it might be possible that

IGF-I produced by tumor cells in the brain crosses the brain-blood barrier and enters the circulation. However, the contribution of locally produced IGF-I leaking into systemic circulation is likely to be small compared with liver production. Based on the attenuation of the association between IGF-I concentration and risk of gliomas, we cannot exclude potential reverse causation.

We did not observe strong and consistent associations of circulating levels of IGF-I, IGFBP-3, or the molar ratio of IGF-I to IGFBP-3 with the risk of gliomas in general. However, high IGF-I concentrations were positively and high IGFBP-3 concentrations were inversely associated with the risk of low-grade gliomas after mutual adjustment, whereas no associations were observed for high-grade gliomas. So far, only one previous epidemiological study examined the association of IGF-I or IGFBP-3 with gliomas. Lönn et al. observed an inverse association of IGF-I concentration with glioma risk, but no association with IGFBP-3 concentration in a case-control study nested within the prospective ATBC trial in Finland (13). Adjustment for age, BMI, smoking, self-reported history of allergies, education, intervention group assignment, time period of diagnosis did not change the results. This study was too small to stratify by glioma grade. In a case-control study, polymorphisms in IGF-I, IGF-II, IGF-I receptor, IGF-II receptor, and IGFBP-3 genes were examined in relation to glioma and meningioma risk (28). The majority of SNPs were not related to glioma risk. Interestingly, however, one SNP in IGF-I and two SNPs in the IGF-I receptor gene were associated with the risk of low- but not high-grade gliomas. The functionality of these polymorphisms, however, appears to be unclear and, thus, an interpretation with respect to our results is difficult. However, one might speculate that there are different genetic pathways that lead to high- and low-grade glioma. IGF-I receptors are overexpressed in gliomas and meningiomas and *in vitro*, IGF-I receptor has been shown to promote mitogenesis and

1 differentiation in glial cells, oligodendrocytes, and neural cells (5). The associations of
2 IGF-I and IGFBP-3 concentrations with low-grade gliomas were attenuated and not
3 statistically significant anymore after excluding the first year of follow-up. This might
4 be due to the even lower number of cases and, thus, more imprecision, but we also
5 cannot exclude a certain extend of reverse causation such that the association is
6 caused by cases diagnosed in the first year of follow-up. However, the number of
7 cases with low-grade glioma diagnosed in the first or even the first two years is too
8 small for a meaningful statistical analysis.

9 Circulating concentrations of IGF-I or IGFBP-3 were generally not associated
10 with the risk of *meningiomas*. The only associations observed in our study were a
11 decreasing meningioma risk with increasing IGF-I/IGFBP-3 ratio in males and in
12 cases that were diagnosed at an earlier age. However, the implications are unclear,
13 especially because the number of meningioma cases among men is small (n=45)
14 and chance might be the reason for this statistically significant finding. This is the first
15 study to examine this association. Previously, Lönn et al. (28) also did not report any
16 association of polymorphisms in IGF-I, IGF-II, IGF-I receptor, IGF-II receptor, and
17 IGFBP-3 genes with meningioma risk.

18 *Acoustic neuromas* (vestibular schwannoma) are benign and slowly growing
19 nerve sheath tumors of the vestibulocochlear nerve. The incidence of this tumor is
20 growing in recent years although this increase could simply be due to improved
21 diagnostic technologies (30). The etiology of this tumor is largely unknown besides
22 an association with moderate to high doses of ionizing radiation, which is a risk factor
23 for all brain tumors. However, ionizing radiation can explain only a small fraction of
24 the tumors. To the best of our knowledge, our finding of a direct association of

1 circulating IGF-I and IGFBP-3 concentrations with acoustic neuromas has not
2 previously been reported.

3 The reason for an inverse association of IGFBP-3 with low-grade gliomas after
4 adjusting for circulating IGF-I and a direct association of IGFBP-3 with acoustic
5 neuromas is unclear. A positive association of IGF-I with acoustic neuromas is
6 consistent with IGF-I's mitogenic effects. The association of IGFBP-3 concentration
7 with cancer risk has first been thought to be inverse as IGFBP-3 is thought to
8 determine the concentration of free, i.e., biologically active, IGF-I in the circulation.
9 However, the results of previous studies on different types of cancer have been
10 inconsistent with some studies indeed showing inverse associations, but some also
11 showing no or even a positive association (14). It has been discussed that different
12 assays measuring concentrations of total or intact IGFBP-3 could cause differences
13 between studies (14), but this does not explain differences in our study between two
14 different types of brain tumors, i.e., different effects of IGFBP-3 on low-grade gliomas
15 and acoustic neuromas. We measured intact IGFBP-3, not total IGFBP-3, which also
16 includes IGFBP-3 fragments that are less biologically active.

17 Our study is so far the second study on IGF-I and IGFBP-3 concentration and
18 risk of brain tumor. Its advantages are its size (505 histologically confirmed primary
19 brain tumors), the prospective design, and the ability to adjust for a number of
20 potential confounders. As in most epidemiological studies, we cannot exclude chance
21 as a possible explanation of our findings, especially as the number of cases in the
22 groups in which we observed statistically significant associations are small. The
23 estimates observed in our study may, thus, be an overestimation of the true effect.
24 Also, the attenuation of the associations observed for low-grade gliomas after
25 excluding the first year of follow-up supports that our results have to be interpreted

1 with care. In addition, we were not able to adjust environmental risk factors such as
2 ionizing radiation. While there is rationale for an inverse association of IGFBP-3 and
3 low-grade glioma, the positive association between IGFBP-3 and risk of acoustic
4 neuromas is difficult to interpret due to the small number of cases.

5

Acknowledgements

The work described in this article was carried out with the financial support of Europe Against Cancer Program of the European Commission (SANCO); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health, Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra; ISCIII RCESP exp. C03/09, Spain; Cancer Research UK; Medical Research Council, United Kingdom; Stroke Association, United Kingdom; British Heart Foundation; Department of Health, United Kingdom; Food Standards Agency, United Kingdom; Wellcome Trust, United Kingdom; Hellenic Ministry of Health, the Stavros Niarchos Foundation and the Hellenic Health Foundation; Italian Association for Research on Cancer (AIRC); Italian National Research Council, Fondazione-Istituto Banco Napoli, Italy; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skåne, Sweden.

References

1. Bondy, ML, Scheurer, ME, Malmer, B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. *Cancer* 2008;113: 1953-68.
2. Khandwala, HM, McCutcheon, IE, Flyvbjerg, A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. *Endocr Rev* 2000;21: 215-244.
3. Joseph D'Ercole, A, and Ye, P. Expanding the Mind: Insulin-Like Growth Factor I and Brain Development. *Endocrinology* 2008;149: 5958-5962.
4. Zumkeller, W, and Westphal, M. The IGF/IGFBP system in CNS malignancy. *Mol Pathol* 2001;54: 227-9.
5. Russo, VC, Gluckman, PD, Feldman, EL, et al. The insulin-like growth factor system and its pleiotropic functions in brain. *Endocr Rev* 2005;26: 916-43.
6. Pollak, MN, Schernhammer, ES, and Hankinson, SE. Insulin-like growth factors and neoplasia. *Nat Rev Cancer* 2004;4: 505-18.
7. Pan, W, and Kastin, AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. *Neuroendocrinology* 2000;72: 171-8.
8. Jones, JL, and Clemmons, DR. Insulin-like growth factors and their binding proteins: biological actions. *Endocr Rev* 1995;16: 3-34.
9. Moore, SC, Rajaraman, P, Dubrow, R, et al. Height, body mass index, and physical activity in relation to glioma risk. *Cancer Res* 2009;69: 8349-55.
10. Gunnell, D, Oliver, SE, Donovan, JL, et al. Do Height-Related Variations in Insulin-Like Growth Factors Underlie the Associations of Stature with Adult Chronic Disease? *J Clin Endocrinol Metab* 2004;89: 213-218.
11. Crowe, FL, Key, TJ, Allen, NE, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Ann Hum Biol* 2010.
12. Baris, D, Gridley, G, Ron, E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. *Cancer Causes Control* 2002;13: 395-400.
13. Lönn, S, Inskip, PD, Pollak, MN, et al. Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors. *Cancer Epidemiol Biomarkers Prev* 2007;16: 844-846.
14. Renehan, AG, Zwahlen, M, Minder, C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *Lancet* 2004;363: 1346-53.
15. Glick, RP, Lichter, T, and Unterman, TG. Insulin-like growth factors in central nervous system tumors. *J Neurooncol* 1997;35: 315-25.
16. Riboli, E, and Kaaks, R. The EPIC Project: rationale and study design. *European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol* 1997;26 Suppl 1: S6-14.
17. Kaaks, R, Slimani, N, and Riboli, E. Pilot phase studies on the accuracy of dietary intake measurements in the EPIC project: overall evaluation of results. *European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol* 1997;26 Suppl 1: S26-36.
18. Haftenberger, M, Lahmann, PH, Panico, S, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Public Health Nutr* 2002;5: 1147-62.
19. Rinaldi, S, Cleveland, R, Norat, T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. *Int J Cancer* 2010;126: 1702-15.

20. Roddam, AW, Allen, NE, Appleby, P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. *Ann Intern Med* 2008;149: 461-71, W83-8.
21. Key, TJ, Appleby, PN, Reeves, GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. *Lancet Oncol* 2010;11: 530-42.
22. Daftary, SS, and Gore, AC. IGF-1 in the brain as a regulator of reproductive neuroendocrine function. *Exp Biol Med (Maywood)* 2005;230: 292-306.
23. Trojan, J, Cloix, JF, Ardourel, MY, et al. Insulin-like growth factor type I biology and targeting in malignant gliomas. *Neuroscience* 2007;145: 795-811.
24. Tranque, PA, Calle, R, Naftolin, F, et al. Involvement of protein kinase-C in the mitogenic effect of insulin-like growth factor-I on rat astrocytes. *Endocrinology* 1992;131: 1948-1954.
25. Åberg, ND, Blomstrand, F, Åberg, MAI, et al. Insulin-like growth factor-I increases astrocyte intercellular gap junctional communication and connexin43 expression in vitro. *J Neuroscience Res* 2003;74: 12-22.
26. Rajah, R, Valentinis, B, and Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. *J Biol Chem* 1997;272: 12181-8.
27. Rajah, R, Lee, KW, and Cohen, P. Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. *Cell Growth Differ* 2002;13: 163-71.
28. Lonn, S, Rothman, N, Shapiro, WR, et al. Genetic variation in insulin-like growth factors and brain tumor risk. *Neuro Oncol* 2008;10: 553-559.
29. Zumkeller, W. IGFs and IGF-binding proteins as diagnostic markers and biological modulators in brain tumors. *Expert Rev Mol Diagn* 2002;2: 473-7.
30. Propp, JM, McCarthy, BJ, Davis, FG, et al. Descriptive epidemiology of vestibular schwannomas. *Neuro-oncol* 2006;8: 1-11.